
USD
( +0.00%
At Close (As of Jan 1, 1970)
$17.71B
Market Cap
14.82
P/E Ratio
1.94
EPS
$33.65
52 Week High
$17.23
52 Week Low
HEALTHCARE
Sector
| Field | Value (DKK) |
|---|---|
| Gross Profit | $21B |
| Total Revenue | $22B |
| Cost Of Revenue | $985M |
| Costof Goods And Services Sold | $985M |
| Operating Income | $6.7B |
| Selling General And Administrative | $3.8B |
| Research And Development | $9.7B |
| Operating Expenses | $14B |
| Investment Income Net | - |
| Net Interest Income | $875M |
| Interest Income | $995M |
| Interest Expense | $120M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $413M |
| Income Before Tax | $9.2B |
| Income Tax Expense | $1.3B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $7.8B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $9.3B |
| Ebitda | $9.7B |
| Net Income | $7.8B |
| Field | Value (DKK) |
|---|---|
| Total Assets | $46B |
| Total Current Assets | $28B |
| Cash And Cash Equivalents At Carrying Value | $9.9B |
| Cash And Short Term Investments | $9.9B |
| Inventory | $62M |
| Current Net Receivables | $6.7B |
| Total Non Current Assets | $18B |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $12B |
| Intangible Assets Excluding Goodwill | $12B |
| Goodwill | $2.5B |
| Investments | - |
| Long Term Investments | $228M |
| Short Term Investments | $11B |
| Other Current Assets | $101M |
| Other Non Current Assets | - |
| Total Liabilities | $9.1B |
| Total Current Liabilities | $5.3B |
| Current Accounts Payable | - |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $92M |
| Total Non Current Liabilities | $3.8B |
| Capital Lease Obligations | $1B |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $1B |
| Other Current Liabilities | $3.5B |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $37B |
| Treasury Stock | - |
| Retained Earnings | $24B |
| Common Stock | $66M |
| Common Stock Shares Outstanding | $646M |
| Field | Value (DKK) |
|---|---|
| Operating Cashflow | $7.8B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $413M |
| Capital Expenditures | $187M |
| Change In Receivables | - |
| Change In Inventory | -$5M |
| Profit Loss | - |
| Cashflow From Investment | -$9.9B |
| Cashflow From Financing | -$3.9B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$4B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $7.8B |
| Field | Value (DKK) |
|---|---|
| Gross Profit | $21B |
| Total Revenue | $22B |
| Cost Of Revenue | $985M |
| Costof Goods And Services Sold | $985M |
| Operating Income | $6.7B |
| Selling General And Administrative | $3.8B |
| Research And Development | $9.7B |
| Operating Expenses | $14B |
| Investment Income Net | - |
| Net Interest Income | $875M |
| Interest Income | $995M |
| Interest Expense | $120M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $413M |
| Income Before Tax | $9.2B |
| Income Tax Expense | $1.3B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $7.8B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $9.3B |
| Ebitda | $9.7B |
| Net Income | $7.8B |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Genmab AS is a prominent biotechnology company based in Copenhagen, Denmark, renowned for its innovative development of specialized antibody therapeutics aimed at treating cancer and other critical illnesses. The company boasts a strong pipeline supported by its proprietary technologies and strategic collaborations, driving advancements in next-generation therapies. With a steadfast commitment to improving patient outcomes through targeted immunotherapies, Genmab is well-positioned to capitalize on opportunities within the dynamic oncology sector.